1. Introduction to Nimesulide, Paracetamol & Chlorzoxazone Tablets – Batch Manufacturing Record (BMR):
The Batch Manufacturing Record (BMR) for Nimesulide, Paracetamol & Chlorzoxazone Tablets is an essential pharmaceutical document that provides detailed instructions and records for manufacturing activities in accordance with Good Manufacturing Practices (GMP). This combination formulation contains Nimesulide BP 100 mg, Paracetamol IP 325 mg, and Chlorzoxazone USP 375 mg per uncoated tablet. Nimesulide is a non-steroidal anti-inflammatory drug (NSAID), Paracetamol acts as an analgesic and antipyretic, while Chlorzoxazone is a centrally acting muscle relaxant. The combination is intended to provide relief from painful musculoskeletal conditions involving inflammation and muscle spasms, subject to applicable regulatory approval. The BMR systematically documents manufacturing operations, including raw material dispensing, sifting, granulation, drying, milling, blending, lubrication, compression, and associated in-process quality checks. It also includes equipment details, material reconciliation, environmental monitoring, batch calculations, quality control testing, and production verification activities. Proper documentation ensures batch traceability, manufacturing consistency, product quality, and regulatory compliance. Each critical manufacturing stage requires appropriate verification by authorized Production and Quality Assurance personnel. The BMR serves as an important reference for batch review, deviation investigation, quality assessment, and final product release, supporting consistent manufacturing practices and patient safety throughout the pharmaceutical production process.
Skip to PDF content2. Manufacturing Process Flow Diagram of Nimesulide, Paracetamol & Chlorzoxazone Tablets:
The manufacturing process flow diagram of Nimesulide, Paracetamol & Chlorzoxazone Tablets illustrates the systematic sequence of operations involved in pharmaceutical tablet production under Good Manufacturing Practices (GMP). Each uncoated tablet contains Nimesulide BP 100 mg, Paracetamol IP 325 mg, and Chlorzoxazone USP 375 mg. The manufacturing process begins with raw material dispensing and sifting to ensure accurate quantities and removal of unwanted particles. The sifted active pharmaceutical ingredients and excipients are processed through pre-mixing, binder preparation, and wet granulation using a Rapid Mass Granulator (RMG). The wet granules are subsequently dried in a Fluid Bed Dryer (FBD) and milled to achieve the required particle size distribution. The dried granules undergo blending and lubrication to promote uniform distribution of ingredients and suitable powder flow properties. The lubricated blend is then compressed into tablets using a suitable compression machine.
During compression, critical quality parameters such as tablet weight variation, hardness, thickness, friability, and disintegration are monitored. Following compression, tablets undergo dedusting, quality inspection, and blister packaging. Packaging checks verify product identification, printed information, and pack integrity. The flow diagram highlights essential In-Process Quality Control (IPQC) checks, equipment utilization, process monitoring, and Quality Assurance verification to support consistent product quality, batch traceability, and regulatory compliance.
Note: The diagram is illustrative. Manufacturing steps, process parameters, and acceptance criteria must follow the approved Master Formula Record and Batch Manufacturing Record.
3. Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) of Nimesulide, Paracetamol & Chlorzoxazone Tablets:
The Critical Process Parameters (CPP) and Critical Quality Attributes (CQA) of Nimesulide, Paracetamol & Chlorzoxazone Tablets play an essential role in ensuring consistent pharmaceutical product quality, manufacturing efficiency, and compliance with Good Manufacturing Practices (GMP). Each uncoated tablet contains Nimesulide BP 100 mg, Paracetamol IP 325 mg, and Chlorzoxazone USP 375 mg.
Critical Process Parameters (CPPs) are manufacturing variables whose variations may affect product quality. Important process parameters include sifting mesh size, blending time, binder concentration, granulation endpoint, impeller speed, drying temperature, loss on drying (LOD), lubrication time, compression force, and blister sealing conditions. These parameters require appropriate monitoring and control during dispensing, granulation, drying, blending, compression, and packaging operations.
Critical Quality Attributes (CQAs) are physical, chemical, biological, or microbiological properties that must remain within established limits to ensure the desired product quality. Important quality attributes include tablet appearance, average weight, weight variation, hardness, thickness, friability, disintegration time, dissolution, assay, content uniformity, related substances, and packaging integrity. Effective control of CPPs helps maintain the required CQAs, minimize batch-to-batch variability, reduce manufacturing deviations, and support product stability.
Conclusion: A scientifically justified relationship between CPPs and CQAs is essential for process validation, Quality Assurance, and consistent manufacturing of Nimesulide, Paracetamol & Chlorzoxazone Tablets in accordance with approved specifications and regulatory requirements.
Note: The parameters and numerical limits shown in the infographic are illustrative. Actual CPP classification and CQA acceptance criteria must be established from product-specific development, risk assessment, process validation, and approved specifications.